Sickle Cell Disease Pipeline Analysis, unmet needs, opportunities, Key Players: Sanofi, Pfizer, Bristol Myers Squibb, Gilead Sciences, Novo Nordisk and Many More

"Sickle Cell Disease Pipeline"

“Sickle Cell Disease Pipeline Insight, 2021” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Sickle cell disease pipeline landscape.

The assessment part of the report embraces in-depth Sickle Cell Disease commercial assessment and clinical assessment of the Sickle Cell Disease pipeline products from the pre-clinical developmental phase to the marketed phase. 

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sickle Cell Disease collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.


Sickle Cell Disease market size is expected to increase during the forecast period owing to the launch of upcoming therapies.


Sickle Cell Disease Companies:

• CSL Behring

• Magenta Therapeutics

• Molecules for Health

• Hillhurst Biopharmaceuticals

• ORYZON therapeutics

• Regenacy Pharmaceuticals

• Dystrogen Therapeutics

• ReveraGen

• Editas Medicine

• Bioverativ ( A Sanofi company)

• Genethon

• Syros Therapeutics

• Gilead Sciences

• Bluebird bio

• CRISPR Therapeutics

• Novo Nordisk

• Forma Therapeutics

• La Jolla

• Merganser Biotech

• NuvOx Pharma

• Pfizer

• Sanofi

• LEO Pharma

• Invenux

• Micelle BioPharma

• AstraZeneca

• Merck Sharp & Dohme

• Angiocrine Bioscience

• Beam Therapeutics

• Fulcrum Therapeutics

• Nicox

• Shire

• TauTona Group

• EpiDestiny

• RadioRx

• Bellicum Pharmaceuticals

• Novartis

• Miltenyi Biotec

• Nova Laboratories

• Gamida-Cell

• Addmedica Sasa

• Bristol Myers Squibb

• Imara

• Ironwood

• ARUVANT (Roivant’s Vant)

• Prolong Pharmaceuticals

• Modus Therapeutics


Request for free sample report:


Sickle Cell Disease Therapies Covered in the Report Include:

  • Innohep
  • Rivipansel
  • BPX-501 T cells
  • Canakinumab
  • EPI01
  • And many more.


Sickle Cell Disease Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Sickle Cell Diseasewith aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late stage of development for the Sickle Cell Disease treatment.
  • Sickle Cell Disease key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Sickle Cell Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the treatment of Sickle Cell Disease.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.  


Request for free sample report:


 Scope of the report

  • The Sickle Cell Disease Pipeline Report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Sickle Cell Disease across the complete product development cycle, including all clinical and non-clinical stages.
  • It comprises detailed profiles of Sickle Cell Disease therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
  • Detailed research and development progress and clinical trial of Sickle Cell Disease, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Sickle Cell Disease.


Report Highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Sickle Cell Disease.    
  • In the coming years, the Sickle Cell Disease market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. 
  • The companies and academics are working to assess challenges and seek opportunities that could influence Sickle Cell Disease Research & Development. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the Sickle Cell Disease treatment market. Several potential therapies for Sickle Cell Disease are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Sickle Cell Disease market size in the coming years.  
  • Our in-depth analysis of the Sickle Cell Disease pipeline assets (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities. 


Request for free sample report:


Table of Content

  1. Report Introduction
  2. Sickle Cell Disease 
  3. Sickle Cell Disease Current Treatment Patterns
  4. Sickle Cell Disease – DelveInsight’s Analytical Perspective
  5. Therapeutic Assessment
  6. Sickle Cell Disease Late Stage Products (Phase-III)
  7. Sickle Cell Disease Mid Stage Products (Phase-II)
  8. Early Stage Products (Phase-I)
  9. Pre-clinical Products and Discovery Stage Products
  10. Inactive Products
  11. Dormant Products
  12. Sickle Cell Disease Discontinued Products
  13. Sickle Cell Disease Product Profiles
  14. Sickle Cell Disease Key Companies
  15. Sickle Cell Disease Key Products
  16. Dormant and Discontinued Products
  17. Sickle Cell Disease Unmet Needs
  18. Sickle Cell Disease Future Perspectives
  19. Sickle Cell Disease Analyst Review  
  20. Appendix
  21. Report Methodology


About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States

Source link